Wolfe Research Cuts Humana (NYSE:HUM) Price Target to $300.00

Humana (NYSE:HUM) had its price target reduced by equities researchers at Wolfe Research from $313.00 to $300.00 in a research report issued on Thursday,MarketScreener reports. The firm currently has an “outperform” rating on the insurance provider’s stock. Wolfe Research’s price objective would suggest a potential upside of 29.89% from the stock’s previous close.

Other equities analysts also recently issued research reports about the stock. Weiss Ratings reissued a “sell (d+)” rating on shares of Humana in a research note on Wednesday, October 8th. Truist Financial reduced their price target on Humana from $300.00 to $285.00 and set a “hold” rating for the company in a research report on Monday, November 10th. Wall Street Zen downgraded Humana from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Piper Sandler reduced their target price on shares of Humana from $288.00 to $272.00 and set a “neutral” rating for the company in a report on Thursday, July 31st. Finally, Sanford C. Bernstein lifted their price objective on shares of Humana from $269.00 to $341.00 and gave the stock an “outperform” rating in a research report on Friday, September 5th. Eight investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $297.67.

Humana Stock Up 0.9%

NYSE HUM traded up $2.06 on Thursday, reaching $230.96. 149,546 shares of the stock traded hands, compared to its average volume of 1,753,305. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95. The company has a fifty day moving average price of $267.88 and a 200-day moving average price of $257.49. The company has a market cap of $27.78 billion, a price-to-earnings ratio of 17.70, a PEG ratio of 1.71 and a beta of 0.42. Humana has a 12 month low of $206.87 and a 12 month high of $315.35.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, November 5th. The insurance provider reported $3.24 EPS for the quarter, beating the consensus estimate of $2.95 by $0.29. Humana had a net margin of 1.28% and a return on equity of 13.67%. The business had revenue of $32.65 billion during the quarter, compared to analyst estimates of $31.99 billion. During the same quarter in the previous year, the business posted $4.16 EPS. The company’s quarterly revenue was up 11.1% compared to the same quarter last year. As a group, research analysts forecast that Humana will post 16.47 EPS for the current fiscal year.

Institutional Investors Weigh In On Humana

A number of large investors have recently bought and sold shares of the company. Cary Street Partners Investment Advisory LLC raised its position in Humana by 63.9% during the first quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider’s stock worth $31,000 after acquiring an additional 46 shares during the period. Elevation Point Wealth Partners LLC acquired a new stake in Humana in the 2nd quarter worth about $32,000. Mather Group LLC. purchased a new stake in Humana during the 3rd quarter worth approximately $34,000. Zions Bancorporation National Association UT acquired a new position in shares of Humana during the first quarter valued at approximately $37,000. Finally, Private Wealth Management Group LLC lifted its position in shares of Humana by 47.5% in the third quarter. Private Wealth Management Group LLC now owns 149 shares of the insurance provider’s stock valued at $39,000 after acquiring an additional 48 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.